| Literature DB >> 32743987 |
Bongyoung Kim1, Young Kyung Yoon2, Dong Sook Kim3, Su Jin Jeong4, Song Vogue Ahn5, Sun Hee Park6, Ki Tae Kwon7, Hong Bin Kim8, Yoon Soo Park4, Shin Woo Kim7, Sungmin Kiem9, Jun Yong Choi10.
Abstract
In 2019, a project designed to develop a system for measuring and comparing antibiotic usage in hospitals was launched in Korea. As part of this project, we developed a means to classify antibiotic usage in Korean hospitals using a modified Delphi method. In results, the following categories of antibiotic classification were accepted for use in Korean hospitals: 1) broad-spectrum antibacterial agents predominantly used for hospital-onset infections in adults, 2) broad-spectrum antibacterial agents predominantly used for community-acquired infections in adults, 3) antibacterial agents predominantly used for resistant gram-positive infections in adults, 4) narrow-spectrum beta-lactam agents in adults, 5) antibacterial agents predominantly used for extensive antibiotic resistant gram-negative bacteria in adults, and 6) total antibacterial agents.Entities:
Keywords: Antibiotics; Hospitals; Korea; Measurement; Stewardship
Mesh:
Substances:
Year: 2020 PMID: 32743987 PMCID: PMC7402924 DOI: 10.3346/jkms.2020.35.e241
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Antibiotic classification in Korean hospitals according to a modified Delphi method
| Classifications | CVR | Mean ± SD | |
|---|---|---|---|
| Broad-spectrum antibacterial agents predominantly used for hospital-onset infections in adultsa | 1.000 | 3.78 ± 0.44 | |
| Broad-spectrum antibacterial agents predominantly used for community-acquired infections in adultsa | 1.000 | 3.78 ± 0.44 | |
| Antibacterial agents predominantly used for resistant gram-positive infections in adultsa | 1.000 | 3.89 ± 0.33 | |
| Narrow-spectrum beta-lactam agents in adultsa | 1.000 | 3.89 ± 0.33 | |
| Antibacterial agents posing the highest risk for | −1.000 | 1.78 ± 0.44 | |
| Antibacterial agents predominantly used for extensive antibiotic resistant gram-negative bacteria in adultsa | 1.000 | 3.89 ± 0.33 | |
| Broad-spectrum antibacterial agents predominantly used for hospital-onset infections in children | −0.111 | 2.67 ± 0.87 | |
| Broad-spectrum antibacterial agents predominantly used for community-acquired infections in children | −0.111 | 2.67 ± 0.87 | |
| Antibacterial agents predominantly used for resistant gram-positive infections in children | −0.556 | 2.22 ± 0.44 | |
| Narrow-spectrum beta-lactam agents for children | −0.111 | 2.67 ± 0.87 | |
| Macrolides for children | −0.556 | 2.00 ± 1.00 | |
| Antibacterial agents posing the highest risk for | −0.778 | 1.78 ± 0.67 | |
| Antifungal agents predominantly used for invasive candidiasis in children | −0.111 | 2.56 ± 0.73 | |
| Antibacterial agents predominantly used for extensive antibiotic resistant bacteria in children | −0.111 | 2.67 ± 0.87 | |
| Agents predominantly used for surgical site infection prophylaxis | 0.333 | 3.11 ± 0.93 | |
| Total antibacterial agenta | 1.000 | 4.00 ± 0.00 | |
CVR = content validity ratio, SD = standard deviation.
aAccepted items.
Consensual definition of antibiotic components according to the antibiotic classification in Korean hospitals
| Antibiotics by classification | CVR | Mean ± SD | |
|---|---|---|---|
| Broad-spectrum antibacterial agents predominantly used for hospital-onset infections in adults | |||
| Amikacin (IV) | 0.750 | 3.25 ± 0.71 | |
| Tobramycin (IV) | 0.750 | 3.00 ± 0.53 | |
| Cefepime | 1.000 | 4.00 ± 0.00 | |
| Ceftazidime | 1.000 | 4.00 ± 0.00 | |
| Imipenem | 1.000 | 4.00 ± 0.00 | |
| Meropenem | 1.000 | 4.00 ± 0.00 | |
| Doripenem | 1.000 | 4.00 ± 0.00 | |
| Piperacillin/tazobactam | 1.000 | 4.00 ± 0.00 | |
| Other 4th generation cephalosporins | 1.000 | 3.75 ± 0.46 | |
| Broad-spectrum antibacterial agents predominantly used for community-acquired infections in adults | |||
| Cefdinir | 1.000 | 3.75 ± 0.46 | |
| Cefixime | 0.750 | 3.75 ± 0.46 | |
| Cefotaxime | 1.000 | 4.00 ± 0.00 | |
| Cefpodoxime | 1.000 | 3.75 ± 0.46 | |
| Ceftriaxone | 1.000 | 4.00 ± 0.00 | |
| Ertapenem | 1.000 | 3.88 ± 0.35 | |
| Gemifloxacin | 1.000 | 3.75 ± 0.46 | |
| Levofloxacin | 1.000 | 3.88 ± 0.35 | |
| Moxifloxacin | 1.000 | 3.88 ± 0.35 | |
| Ciprofloxacin | 1.000 | 3.88 ± 0.35 | |
| Other fluoroquinolones | 0.750 | 3.63 ± 0.74 | |
| Other 3rd generation cephalosporins | 0.750 | 3.13 ± 0.64 | |
| Antibacterial agents predominantly used for resistant gram-positive infections in adults | |||
| Linezolid | 1.000 | 4.00 ± 0.00 | |
| Vancomycin (IV) | 1.000 | 4.00 ± 0.00 | |
| Teicoplanin | 1.000 | 4.00 ± 0.00 | |
| Narrow-spectrum beta-lactam agents in adults | |||
| Amoxicillin | 1.000 | 4.00 ± 0.00 | |
| Amoxicillin/clavulanate | 1.000 | 3.88 ± 0.35 | |
| Ampicillin | 1.000 | 3.88 ± 0.35 | |
| Ampicillin/sulbactam | 1.000 | 3.88 ± 0.35 | |
| Nafcillin | 1.000 | 3.88 ± 0.35 | |
| Cefadroxil | 1.000 | 3.75 ± 0.46 | |
| Cefazolin | 1.000 | 3.88 ± 0.35 | |
| Cephalexin | 1.000 | 3.75 ± 0.46 | |
| Cefotetan | 1.000 | 3.62 ± 0.52 | |
| Cefoxitin | 1.000 | 3.62 ± 0.52 | |
| Cefaclor | 0.750 | 3.63 ± 0.74 | |
| Cefprozil | 0.750 | 3.63 ± 0.74 | |
| Other 1st generation cephalosporins | 0.750 | 3.50 ± 0.76 | |
| Other 2nd generation cephalosporins | 0.500 | 3.38 ± 0.92 | |
| Antibacterial agents predominantly used for extensive antibiotic resistant gram-negative bacteria in adults | |||
| Colistin (IV) | 1.000 | 4.00 ± 0.00 | |
| Tigecycline | 1.000 | 3.88 ± 0.35 | |
| Ceftolozane/tazobactam | 1.000 | 3.75 ± 0.46 | |
CVR = content validity ratio, SD = standard deviation, IV = intravenous.